WCN25-318 FELZARTAMAB DURABLY REDUCES DISEASE RELEVANT BIOMARKERS THROUGH TARGETING OF CD38+ PLASMA CELLS AND PLASMABLASTS, THE UPSTREAM DRIVERS OF IgA NEPHROPATHY (IgAN)

Saved in:
Bibliographic Details
Main Authors: Lisa Kivman, Tabea Kraft, Julia Rauser, Rainer Boxhammer, Stefan Hartle, Brian Schwartz, Paul Manser, Leslie Chinn, Uptal Patel, Donna Flesher, Krzysztof Kiryluk, Jonathan Barratt
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:Kidney International Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024924023763
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849690909808001024
author Lisa Kivman
Tabea Kraft
Julia Rauser
Rainer Boxhammer
Stefan Hartle
Brian Schwartz
Paul Manser
Leslie Chinn
Uptal Patel
Donna Flesher
Krzysztof Kiryluk
Jonathan Barratt
author_facet Lisa Kivman
Tabea Kraft
Julia Rauser
Rainer Boxhammer
Stefan Hartle
Brian Schwartz
Paul Manser
Leslie Chinn
Uptal Patel
Donna Flesher
Krzysztof Kiryluk
Jonathan Barratt
author_sort Lisa Kivman
collection DOAJ
format Article
id doaj-art-1ca8206ec8664d0c8b3c4e5eba14dbc3
institution DOAJ
issn 2468-0249
language English
publishDate 2025-02-01
publisher Elsevier
record_format Article
series Kidney International Reports
spelling doaj-art-1ca8206ec8664d0c8b3c4e5eba14dbc32025-08-20T03:21:11ZengElsevierKidney International Reports2468-02492025-02-01102S173S17410.1016/j.ekir.2024.11.354WCN25-318 FELZARTAMAB DURABLY REDUCES DISEASE RELEVANT BIOMARKERS THROUGH TARGETING OF CD38+ PLASMA CELLS AND PLASMABLASTS, THE UPSTREAM DRIVERS OF IgA NEPHROPATHY (IgAN)Lisa Kivman0Tabea Kraft1Julia Rauser2Rainer Boxhammer3Stefan Hartle4Brian Schwartz5Paul Manser6Leslie Chinn7Uptal Patel8Donna Flesher9Krzysztof Kiryluk10Jonathan Barratt11Biomarkers and Bioanalytical Sciences, Human Immunology Biosciences, Inc, a Biogen company, South San Francisco, United StatesClinical Biomarkers, Morphosys AG, Planegg, GermanyClinical Pharmacology, MorphoSys AG, Planegg, GermanyClinical Biomarkers, Morphosys AG, Planegg, GermanyClinical Pharmacology, MorphoSys AG, Planegg, GermanyClinical Development, Human Immunology Biosciences, Inc, a Biogen Company, South San Francisco, United StatesBiostatistics, Human Immunology Biosciences, Inc, a Biogen Company, South San Francisco, United StatesClinical Pharmacology, Human Immunology Biosciences, Inc, a Biogen Company, South San Francisco, United StatesClinical Development, Human Immunology Biosciences, Inc, a Biogen Company, South San Francisco, United StatesBiomarker and Bioanalytical Sciences, Human Immunology Biosciences, Inc, a Biogen Company, South San Francisco, United StatesDivision of Nephrology, Department of Medicine, Columbia University, New York, United StatesMayer IgA Nephropathy Laboratory, University of Leicester, Leicester, United Kingdomhttp://www.sciencedirect.com/science/article/pii/S2468024924023763
spellingShingle Lisa Kivman
Tabea Kraft
Julia Rauser
Rainer Boxhammer
Stefan Hartle
Brian Schwartz
Paul Manser
Leslie Chinn
Uptal Patel
Donna Flesher
Krzysztof Kiryluk
Jonathan Barratt
WCN25-318 FELZARTAMAB DURABLY REDUCES DISEASE RELEVANT BIOMARKERS THROUGH TARGETING OF CD38+ PLASMA CELLS AND PLASMABLASTS, THE UPSTREAM DRIVERS OF IgA NEPHROPATHY (IgAN)
Kidney International Reports
title WCN25-318 FELZARTAMAB DURABLY REDUCES DISEASE RELEVANT BIOMARKERS THROUGH TARGETING OF CD38+ PLASMA CELLS AND PLASMABLASTS, THE UPSTREAM DRIVERS OF IgA NEPHROPATHY (IgAN)
title_full WCN25-318 FELZARTAMAB DURABLY REDUCES DISEASE RELEVANT BIOMARKERS THROUGH TARGETING OF CD38+ PLASMA CELLS AND PLASMABLASTS, THE UPSTREAM DRIVERS OF IgA NEPHROPATHY (IgAN)
title_fullStr WCN25-318 FELZARTAMAB DURABLY REDUCES DISEASE RELEVANT BIOMARKERS THROUGH TARGETING OF CD38+ PLASMA CELLS AND PLASMABLASTS, THE UPSTREAM DRIVERS OF IgA NEPHROPATHY (IgAN)
title_full_unstemmed WCN25-318 FELZARTAMAB DURABLY REDUCES DISEASE RELEVANT BIOMARKERS THROUGH TARGETING OF CD38+ PLASMA CELLS AND PLASMABLASTS, THE UPSTREAM DRIVERS OF IgA NEPHROPATHY (IgAN)
title_short WCN25-318 FELZARTAMAB DURABLY REDUCES DISEASE RELEVANT BIOMARKERS THROUGH TARGETING OF CD38+ PLASMA CELLS AND PLASMABLASTS, THE UPSTREAM DRIVERS OF IgA NEPHROPATHY (IgAN)
title_sort wcn25 318 felzartamab durably reduces disease relevant biomarkers through targeting of cd38 plasma cells and plasmablasts the upstream drivers of iga nephropathy igan
url http://www.sciencedirect.com/science/article/pii/S2468024924023763
work_keys_str_mv AT lisakivman wcn25318felzartamabdurablyreducesdiseaserelevantbiomarkersthroughtargetingofcd38plasmacellsandplasmablaststheupstreamdriversofiganephropathyigan
AT tabeakraft wcn25318felzartamabdurablyreducesdiseaserelevantbiomarkersthroughtargetingofcd38plasmacellsandplasmablaststheupstreamdriversofiganephropathyigan
AT juliarauser wcn25318felzartamabdurablyreducesdiseaserelevantbiomarkersthroughtargetingofcd38plasmacellsandplasmablaststheupstreamdriversofiganephropathyigan
AT rainerboxhammer wcn25318felzartamabdurablyreducesdiseaserelevantbiomarkersthroughtargetingofcd38plasmacellsandplasmablaststheupstreamdriversofiganephropathyigan
AT stefanhartle wcn25318felzartamabdurablyreducesdiseaserelevantbiomarkersthroughtargetingofcd38plasmacellsandplasmablaststheupstreamdriversofiganephropathyigan
AT brianschwartz wcn25318felzartamabdurablyreducesdiseaserelevantbiomarkersthroughtargetingofcd38plasmacellsandplasmablaststheupstreamdriversofiganephropathyigan
AT paulmanser wcn25318felzartamabdurablyreducesdiseaserelevantbiomarkersthroughtargetingofcd38plasmacellsandplasmablaststheupstreamdriversofiganephropathyigan
AT lesliechinn wcn25318felzartamabdurablyreducesdiseaserelevantbiomarkersthroughtargetingofcd38plasmacellsandplasmablaststheupstreamdriversofiganephropathyigan
AT uptalpatel wcn25318felzartamabdurablyreducesdiseaserelevantbiomarkersthroughtargetingofcd38plasmacellsandplasmablaststheupstreamdriversofiganephropathyigan
AT donnaflesher wcn25318felzartamabdurablyreducesdiseaserelevantbiomarkersthroughtargetingofcd38plasmacellsandplasmablaststheupstreamdriversofiganephropathyigan
AT krzysztofkiryluk wcn25318felzartamabdurablyreducesdiseaserelevantbiomarkersthroughtargetingofcd38plasmacellsandplasmablaststheupstreamdriversofiganephropathyigan
AT jonathanbarratt wcn25318felzartamabdurablyreducesdiseaserelevantbiomarkersthroughtargetingofcd38plasmacellsandplasmablaststheupstreamdriversofiganephropathyigan